194 related articles for article (PubMed ID: 36880458)
1. RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
Ciscar M; Trinidad EM; Perez-Chacon G; Alsaleem M; Jimenez M; Jimenez-Santos MJ; Perez-Montoyo H; Sanz-Moreno A; Vethencourt A; Toss M; Petit A; Soler-Monso MT; Lopez V; Gomez-Miragaya J; Gomez-Aleza C; Dobrolecki LE; Lewis MT; Bruna A; Mouron S; Quintela-Fandino M; Al-Shahrour F; Martinez-Aranda A; Sierra A; Green AR; Rakha E; Gonzalez-Suarez E
EMBO Mol Med; 2023 Apr; 15(4):e16715. PubMed ID: 36880458
[TBL] [Abstract][Full Text] [Related]
2. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
3. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
4. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.
Gómez-Aleza C; Nguyen B; Yoldi G; Ciscar M; Barranco A; Hernández-Jiménez E; Maetens M; Salgado R; Zafeiroglou M; Pellegrini P; Venet D; Garaud S; Trinidad EM; Benítez S; Vuylsteke P; Polastro L; Wildiers H; Simon P; Lindeman G; Larsimont D; Van den Eynden G; Velghe C; Rothé F; Willard-Gallo K; Michiels S; Muñoz P; Walzer T; Planelles L; Penninger J; Azim HA; Loi S; Piccart M; Sotiriou C; González-Suárez E
Nat Commun; 2020 Dec; 11(1):6335. PubMed ID: 33303745
[TBL] [Abstract][Full Text] [Related]
6. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
8. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
9. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
10. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
11. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
12. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
13. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
[TBL] [Abstract][Full Text] [Related]
14. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
15. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
16. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
17. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
[TBL] [Abstract][Full Text] [Related]
18. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
19. OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer.
Sänger N; Ruckhäberle E; Bianchini G; Heinrich T; Milde-Langosch K; Müller V; Rody A; Solomayer EF; Fehm T; Holtrich U; Becker S; Karn T
Mol Oncol; 2014 Oct; 8(7):1196-207. PubMed ID: 24785095
[TBL] [Abstract][Full Text] [Related]
20. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
